慢性髓性白血病无治疗缓解与分子复发的综合分子特征:EURO-SKI生物标志物研究
EURO-SKI试验旨在研究慢性髓性白血病(CML)患者停用酪氨酸激酶抑制剂(TKI)。本研究对240例CML患者(训练集122例,验证集118例)及10例健康对照进行全转录组基因表达分析,并结合NanoString nCounter绝对基因定量。研究发现无治疗缓解(TFR)患者红系祖细胞调控子GATA1、KLF1和MYBL1活化,先天与适应性免疫细胞间通讯持续存在,而TFR丢失患者该通讯被破坏;并识别出FLT3阈值可区分TFR丢失概率显著不同的两组患者。
要点
- TFR患者红系祖细胞调控子GATA1、KLF1和MYBL1活化。
- TFR患者维持先天与适应性免疫细胞间通讯,类似健康对照。
- TFR丢失患者先天与适应性免疫细胞间通讯被破坏。
核心结论
- TFR患者红系祖细胞调控子活化并维持先天与适应性免疫细胞间通讯,TFR丢失患者该通讯被破坏。
- FLT3阈值可区分TFR丢失概率显著不同的两组患者。
研究设计与样本
- EURO-SKI试验中,对240例CML患者停用TKI最后一天的外周血白细胞进行全转录组基因表达分析(训练集n=122,验证集n=118)。
- 纳入10例健康对照,并整合外部96例TKI初治CML患者转录组数据。
主要发现
- TFR患者显示红系祖细胞特征性的GATA1、KLF1和MYBL1调控子活化。
- TFR患者维持先天免疫(自然杀伤细胞和树突状细胞)与适应性免疫(CD8+、CD4+和γδ T淋巴细胞)之间的持续通讯,镜像健康对照模式。
- TFR丢失患者先天与适应性免疫细胞间通讯被破坏。
- 识别出FLT3阈值可区分TFR丢失概率显著不同的两组患者。
临床怎么用
- 利用重建或强化先天与适应性免疫通讯的机制可能对实现持久TFR至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Stop Kinase Inhibitors (EURO-SKI) trial was launched to investigate the discontinuation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). The molecular mechanisms underlying sustained treatment-free remission (TFR) and loss of TFR, are still poorly understood. To address this, we performed whole transcriptome gene expression analyses coupled with NanoString nCounter-based absolute gene quantification. Gene expression was assessed in peripheral blood leukocytes from 240 CML patients on the final day of TKI intake (training sample: n = 122, validation sample: n = 118) as well as from 10 healthy controls. To identify TKI-specific mechanisms, transcriptomic data from an external dataset of 96 TKI-naïve CML patients was incorporated into our analyses. TFR patients showed an activation of GATA1, KLF1 and MYBL1 regulons characteristic for erythroid progenitor cells. TFR patients maintain persistent communication between innate (natural killer and dendritic cells) and adaptive immunity (e.g., CD8+, CD4+, and γδ T lymphocytes), mirroring patterns observed in healthy controls. This intercellular communication is disrupted in patients with loss of TFR. Furthermore, we identified an FLT3 threshold that distinguished two patient groups with significantly different probabilities of TFR loss. Leveraging mechanisms that reestablish or reinforce the communication between innate and adaptive immunity could be pivotal in achieving durable TFR.
引用
- Rinaldetti S, Chepeleva M, Hedblom A, et al. Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Leukemia. 2026. PMID: 42315627. doi:10.1038/s41375-026-03001-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。